CCR4 Modulator Compounds for Targeted Chemokine Receptor Inhibition

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

The identification of compounds that modulate CCR4 function is an ongoing challenge, impacting the management of inflammation-related disorders.

Innovation Solution

Development of compounds with specific structural formulas that inhibit CCR4, including pharmaceutical compositions and methods for administering these compounds to inhibit CCR4 activity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If conventional approaches are used to identify CCR4 modulators, then the process is time-consuming and inefficient, but the patent provides specific chemical structures and methods to accelerate discovery

Engineering Contradiction:

Improvecompound identification efficiencyVSAvoidtime for CCR4 modulator discovery

Core Design Contradiction:

ProductivityVSLoss of time

Solution Approach 1:

The patent performs preliminary action by pre-designing and providing specific chemical structures (Formula I and Formula II) with defined substituent patterns and structural features that are predicted to modulate CCR4. This preliminary structuring of compounds with specific pharmacophore elements enables faster screening and identification of active modulators without requiring de novo discovery for each candidate.

Inventive Principle:

Principle #10Preliminary action

2Reliability

If broad screening of compounds is performed to find CCR4 modulators, then the chance of finding effective compounds increases, but the complexity and resource requirements increase

Engineering Contradiction:

Improveeffectiveness of CCR4 modulatorVSAvoidscreening process complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent applies local quality by defining specific structural features and substituent patterns within the chemical formulas that are critical for CCR4 modulation. Rather than relying on broad, non-specific screening, the invention identifies and emphasizes particular local structural characteristics (such as specific ring systems, substituent positions, and molecular features) that confer CCR4 modulatory activity, enabling more targeted and efficient compound evaluation.

Inventive Principle:

Principle #3Local quality

Data Source

PatentUS20260092050A1Chemokine receptor modulators and uses thereof

Publication Date: 2026.04.02 RAPT THERAPEUTICS INC

AI summary

Disclosed herein, inter alia, are compounds and methods of use thereof for the modulation of certain chemokine receptor activity.